HS6ST2

Summary

HS6ST2 (heparan sulfate 6-O-sulfotransferase 2, HGNC:19133) is a protein-coding gene on chromosome Xq26.2, encoding Heparan-sulfate 6-O-sulfotransferase 2 (Q96MM7). 6-O-sulfation enzyme which catalyzes the transfer of sulfate from 3’-phosphoadenosine 5’-phosphosulfate (PAPS) to position 6 of the N-sulfoglucosamine residue (GlcNS) of heparan sulfate.

Heparan sulfate proteoglycans are ubiquitous components of the cell surface, extracellular matrix, and basement membranes, and interact with various ligands to influence cell growth, differentiation, adhesion, and migration. This gene encodes a member of the heparan sulfate (HS) sulfotransferase gene family, which catalyze the transfer of sulfate to HS. Different family members and isoforms are thought to synthesize heparan sulfates with tissue-specific structures and functions. Multiple transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 90161 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Paganini-Miozzo syndrome (Limited, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 118 total — 1 pathogenic
• Phenotypes (HPO): 26
• MANE Select transcript: NM_001394073

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19133
Approved symbol	HS6ST2
Name	heparan sulfate 6-O-sulfotransferase 2
Location	Xq26.2
Locus type	gene with protein product
Status	Approved
Aliases	HS6ST-2
Ensembl gene	ENSG00000171004
Ensembl biotype	protein_coding
OMIM	300545
Entrez	90161

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000370833, ENST00000370836, ENST00000406696, ENST00000521489, ENST00000602570, ENST00000640529

RefSeq mRNA: 4 — MANE Select: NM_001394073 NM_001077188, NM_001394073, NM_001394074, NM_147175

CCDS: CCDS48169, CCDS48170

Canonical transcript exons

ENST00000370833 — 5 exons

Exon	Start	End
ENSE00001154195	132669113	132669199
ENSE00001154202	132708462	132708494
ENSE00003459518	132956808	132957326
ENSE00003719920	132958175	132958629
ENSE00003808713	132626015	132629093

Expression profiles

Bgee: expression breadth ubiquitous, 215 present calls, max score 97.50.

FANTOM5 (CAGE): breadth broad, TPM avg 3.7773 / max 334.7052, expressed in 623 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200543	1.1502	424
200539	1.0561	297
200541	0.4361	284
200542	0.3292	189
200540	0.2477	162
200545	0.1835	105
200544	0.1300	52
200532	0.1272	44
200538	0.0623	26
200547	0.0403	12

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	97.50	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.50	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.30	gold quality
renal medulla	UBERON:0000362	92.16	gold quality
esophagus squamous epithelium	UBERON:0006920	90.92	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.21	gold quality
middle temporal gyrus	UBERON:0002771	87.99	gold quality
placenta	UBERON:0001987	86.34	gold quality
ventricular zone	UBERON:0003053	85.92	gold quality
entorhinal cortex	UBERON:0002728	84.89	gold quality
Brodmann (1909) area 46	UBERON:0006483	84.31	gold quality
primary visual cortex	UBERON:0002436	84.12	gold quality
superior vestibular nucleus	UBERON:0007227	82.95	gold quality
ganglionic eminence	UBERON:0004023	82.75	gold quality
gingival epithelium	UBERON:0001949	82.58	gold quality
occipital lobe	UBERON:0002021	82.49	gold quality
lateral globus pallidus	UBERON:0002476	82.49	gold quality
germinal epithelium of ovary	UBERON:0001304	82.31	gold quality
oral cavity	UBERON:0000167	82.27	gold quality
nucleus accumbens	UBERON:0001882	81.57	gold quality
postcentral gyrus	UBERON:0002581	80.70	gold quality
substantia nigra pars compacta	UBERON:0001965	80.64	gold quality
parietal lobe	UBERON:0001872	80.29	gold quality
caput epididymis	UBERON:0004358	80.11	gold quality
superior frontal gyrus	UBERON:0002661	80.02	gold quality
cerebellar vermis	UBERON:0004720	79.94	gold quality
left ovary	UBERON:0002119	79.67	gold quality
gingiva	UBERON:0001828	79.09	gold quality
ovary	UBERON:0000992	79.03	gold quality
dorsal plus ventral thalamus	UBERON:0001897	78.58	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	59.29
E-ANND-3	yes	3.57

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 8)

• we have characterized HS6ST-2 and HS6ST-1 human isologues, including their chromosomal localizations,HS6STs could also transfer sulfate to N -sulfoglucosamine residues located at the non-reducing terminal of HS with high affinity. (PMID:12492399)
• HS6ST2 knockdown disrupts epithelial-mesenchymal transition and suggesets that HS6ST2 potentiates Notch signaling in pancreatic cancer cells. (PMID:21443520)
• HS6ST-1 and HS6ST-2 have roles in regulating the angiogenic program in ovarian cancer cells affecting HB-EGF signaling and subsequent expression of angiogenic cytokines by cancer cells (PMID:24563483)
• RT-PCR analysis showed that the overall transcriptional activity of the main Heparan Sulfate biosynthesis-involved genes (EXT1, EXT2, NDST1, NDST2, GLCE, HS2ST1, HS3ST1, HS3ST2, HS6ST1, HS6ST2, SULF1, SULF2, HPSE) was decreased by 1.5-2-fold in Grade II-III glioma. (PMID:29104277)
• downregulated HS6ST2 targeted by miR-23b-3p promotes matrix degradation by activating p38 MAPK in chondrocytes and OA cartilage. (PMID:29899528)
• we identified a novel c.916G>C variant in the HS6ST2 gene. The mutation caused a significantly reduction in HS6ST2 6-O-sulfotransferase activity and was associated with a previously undescribed form of syndromic XLID with severe congenital myopia (PMID:30471091)
• Role of lncRNA FAM83H antisense RNA1 (FAM83H-AS1) in the progression of non-small cell lung cancer by regulating the miR-545-3p/heparan sulfate 6-O-sulfotransferase (HS6ST2) axis. (PMID:35260044)
• Downregulation of HS6ST2 Inhibits Cervical Cancer Cell Migration and Invasion in Vivo and in Vitro. (PMID:38058080)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	hs6st2	ENSDARG00000012025
mus_musculus	Hs6st2	ENSMUSG00000062184
rattus_norvegicus	Hs6st2	ENSRNOG00000030880
drosophila_melanogaster	Hs6st	FBGN0038755
caenorhabditis_elegans		WBGENE00002031

Paralogs (2): HS6ST1 (ENSG00000136720), HS6ST3 (ENSG00000185352)

Protein

Protein identifiers

Heparan-sulfate 6-O-sulfotransferase 2 — Q96MM7 (reviewed: Q96MM7)

All UniProt accessions (2): Q96MM7, A0A1W2PQ14

UniProt curated annotations — full annotation on UniProt →

Function. 6-O-sulfation enzyme which catalyzes the transfer of sulfate from 3’-phosphoadenosine 5’-phosphosulfate (PAPS) to position 6 of the N-sulfoglucosamine residue (GlcNS) of heparan sulfate.

Subcellular location. Membrane.

Disease relevance. Paganini-Miozzo syndrome (MRXSPM) [MIM:301025] An X-linked, syndromic, neurodevelopmental disorder characterized by intellectual disability, global developmental delay, severe myopia, and mild facial dysmorphism. The disease may be caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the sulfotransferase 6 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q96MM7-1	1	yes
Q96MM7-2	2, HS6ST-2S
Q96MM7-3	3, HS6ST-2
Q96MM7-4	4

RefSeq proteins (4): NP_001070656, NP_001381002, NP_001381003, NP_671704 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005331	Sulfotransferase	Family
IPR010635	Heparan_SO4-6-sulfoTrfase	Family
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF03567

Catalyzed reactions (Rhea), 1 shown:

• alpha-D-glucosaminyl-heparan sulfate + 3’-phosphoadenylyl sulfate = 6-sulfo-alpha-D-glucosaminyl-heparan sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:56604)

UniProt features (39 total): binding site 11, glycosylation site 8, sequence conflict 6, compositionally biased region 3, topological domain 2, splice variant 2, sequence variant 2, region of interest 2, chain 1, transmembrane region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96MM7-F1	74.28	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 290 (proton acceptor)

Ligand- & substrate-binding residues (11): 233–241; 263–264; 280; 285; 290; 325; 333; 337; 344; 457–459; 463–464

Glycosylation sites (8): 209, 404, 460, 544, 556, 564, 589, 592

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-2022928	HS-GAG biosynthesis

MSigDB gene sets: 212 (showing top): AP1_01, WHITEHURST_PACLITAXEL_SENSITIVITY, GOZGIT_ESR1_TARGETS_DN, CREBP1_Q2, TGACCTY_ERR1_Q2, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, SREBP1_02, IRF7_01, GOBP_HEPARAN_SULFATE_PROTEOGLYCAN_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, TGCTGAY_UNKNOWN, E4F1_Q6, OCT1_07, ATF3_Q6, SLEBOS_HEAD_AND_NECK_CANCER_WITH_HPV_UP

GO Biological Process (1): heparan sulfate proteoglycan biosynthetic process (GO:0015012)

GO Molecular Function (3): heparan sulfate 6-sulfotransferase activity (GO:0017095), sulfotransferase activity (GO:0008146), transferase activity (GO:0016740)

GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Heparan sulfate/heparin (HS-GAG) metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
proteoglycan biosynthetic process	1
heparan sulfate proteoglycan metabolic process	1
protein O-linked glycosylation via xylose	1
heparan sulfate sulfotransferase activity	1
transferase activity, transferring sulphur-containing groups	1
catalytic activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

820 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HS6ST2	HS2ST1	Q7LGA3	721
HS6ST2	NDST2	P52849	670
HS6ST2	HS3ST1	O14792	662
HS6ST2	NDST1	P52848	652
HS6ST2	GLCE	O94923	645
HS6ST2	EXT1	Q16394	581
HS6ST2	SULF2	Q8IWU5	579
HS6ST2	NDST3	O95803	571
HS6ST2	GPC3	P51654	568
HS6ST2	HS3ST3A1	Q9Y663	557
HS6ST2	SULF1	Q8IWU6	556
HS6ST2	HS3ST4	Q9Y661	547
HS6ST2	HS3ST6	Q96QI5	543
HS6ST2	HS3ST5	Q8IZT8	522
HS6ST2	NDST4	Q9H3R1	518

IntAct

69 interactions, top by confidence:

A	B	Type	Score
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
YWHAZ	BLTP3B	psi-mi:“MI:0914”(association)	0.530
	PLOD2	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
OGFOD3	CLGN	psi-mi:“MI:0914”(association)	0.530
PON2	NPC1	psi-mi:“MI:0914”(association)	0.530
LGALS1	LAMA5	psi-mi:“MI:0914”(association)	0.530
GINM1	ADCY9	psi-mi:“MI:0914”(association)	0.530
ANKH	FAM234B	psi-mi:“MI:0914”(association)	0.530
KIF20A	NEURL4	psi-mi:“MI:0914”(association)	0.350
NETO2	TIA1	psi-mi:“MI:0914”(association)	0.350
Pafah1b1	ATXN3	psi-mi:“MI:0914”(association)	0.350
	SURF4	psi-mi:“MI:0914”(association)	0.350
CACNA1C	DISP2	psi-mi:“MI:0914”(association)	0.350
HCN1	POTEF	psi-mi:“MI:0914”(association)	0.350
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
LDLRAD1	GXYLT2	psi-mi:“MI:0914”(association)	0.350
PDGFRA	GXYLT2	psi-mi:“MI:0914”(association)	0.350
CLEC12B	GXYLT2	psi-mi:“MI:0914”(association)	0.350
GINM1	FAM234B	psi-mi:“MI:0914”(association)	0.350
CHRNB2	TMEM131L	psi-mi:“MI:0914”(association)	0.350
ST14	LIPT2	psi-mi:“MI:0914”(association)	0.350
SCGB2A2	RTL8C	psi-mi:“MI:0914”(association)	0.350
NRSN1	FAM171A2	psi-mi:“MI:0914”(association)	0.350
TMEM59	GPR89A	psi-mi:“MI:0914”(association)	0.350
CHRNB4	GPR89A	psi-mi:“MI:0914”(association)	0.350
C1orf54	AGRN	psi-mi:“MI:0914”(association)	0.350
C1QTNF7	AGRN	psi-mi:“MI:0914”(association)	0.350

BioGRID (76): HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-RNA), HS6ST2 (Affinity Capture-MS), HS6ST2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8C2LVE3, A0MGZ5, A0MGZ7, A4IID1, A5D7I4, A9X1C8, O08889, O12971, O60243, O93336, O97583, P0DJQ9, P52849, P52850, P61642, P69478, P97464, Q16394, Q56UJ5, Q5IGR7, Q5IGR8, Q5R621, Q5RBC3, Q5U4X8, Q6GQK9, Q6KFX9, Q6ZXD2, Q76KB1, Q76KB2, Q7LFX5, Q7LGA3, Q7T3S3, Q800H9, Q80UW0, Q86V40, Q8CHI9, Q8IZP7, Q8R3H7, Q91XQ5, Q91ZB4

Diamond homologs: A0MGZ5, A0MGZ7, O60243, Q56UJ5, Q76KB2, Q76LW2, Q800H9, Q80UW0, Q8IZP7, Q91ZB4, Q96MM7, Q9QYK4, Q9QYK5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

118 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	80
Likely benign	9
Benign	5

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
633697	NM_001394073.1(HS6ST2):c.916G>C (p.Gly306Arg)	Pathogenic

SpliceAI

3682 predictions. Top by Δscore:

Variant	Effect	Δscore
X:132629092:TCC:T	acceptor_loss	1.0000
X:132629093:CCT:C	acceptor_loss	1.0000
X:132629094:C:CC	acceptor_gain	1.0000
X:132629095:T:G	acceptor_loss	1.0000
X:132629100:A:AC	acceptor_gain	1.0000
X:132710259:G:C	acceptor_gain	1.0000
X:132629090:GTTC:G	acceptor_gain	0.9900
X:132629091:TTC:T	acceptor_gain	0.9900
X:132629092:TC:T	acceptor_gain	0.9900
X:132629093:CC:C	acceptor_gain	0.9900
X:132629100:A:C	acceptor_gain	0.9900
X:132710247:CA:C	acceptor_gain	0.9900
X:132710248:A:AC	acceptor_gain	0.9900
X:132710248:A:C	acceptor_gain	0.9900
X:132710259:G:GC	acceptor_gain	0.9900
X:132758254:A:AC	donor_gain	0.9900
X:132758255:C:CC	donor_gain	0.9900
X:132841263:C:T	acceptor_gain	0.9900
X:132956805:CACC:C	donor_loss	0.9900
X:132956806:A:AC	donor_gain	0.9900
X:132956806:ACCT:A	donor_loss	0.9900
X:132956807:C:A	donor_loss	0.9900
X:132956807:C:CC	donor_gain	0.9900
X:132957325:CG:C	acceptor_gain	0.9900
X:132629089:AGTTC:A	acceptor_gain	0.9800
X:132639632:A:AC	donor_gain	0.9800
X:132639633:C:CC	donor_gain	0.9800
X:132710240:CAAAG:C	acceptor_gain	0.9800
X:132710241:A:T	acceptor_gain	0.9800
X:132841263:C:CT	acceptor_gain	0.9800

AlphaMissense

4241 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:132628547:C:A	R498S	1.000
X:132628547:C:G	R498S	1.000
X:132628548:C:A	R498M	1.000
X:132628548:C:G	R498T	1.000
X:132628560:A:G	L494P	1.000
X:132628569:G:T	A491D	1.000
X:132628570:C:G	A491P	1.000
X:132628590:T:A	D484V	1.000
X:132628590:T:G	D484A	1.000
X:132628591:C:A	D484Y	1.000
X:132628591:C:G	D484H	1.000
X:132628598:A:C	N481K	1.000
X:132628598:A:T	N481K	1.000
X:132628673:A:C	F456L	1.000
X:132628673:A:T	F456L	1.000
X:132628674:A:C	F456C	1.000
X:132628674:A:G	F456S	1.000
X:132628675:A:G	F456L	1.000
X:132628685:A:C	F452L	1.000
X:132628685:A:T	F452L	1.000
X:132628686:A:C	F452C	1.000
X:132628686:A:G	F452S	1.000
X:132628687:A:G	F452L	1.000
X:132628698:A:G	F448S	1.000
X:132628699:A:T	F448I	1.000
X:132628706:C:A	E445D	1.000
X:132628706:C:G	E445D	1.000
X:132628707:T:A	E445V	1.000
X:132628709:A:C	F444L	1.000
X:132628709:A:T	F444L	1.000

dbSNP variants (sampled 300 via entrez): RS1000013089 (X:132780340 T>A), RS1000024263 (X:132879453 T>C,G), RS1000037374 (X:132668198 G>A,C), RS1000046375 (X:132946632 C>G,T), RS1000046849 (X:132798084 A>G), RS1000047775 (X:132857412 A>G), RS1000063846 (X:132934705 T>C), RS1000076982 (X:132661063 C>T), RS1000115174 (X:132724662 A>C), RS1000115883 (X:132634029 T>C), RS1000140273 (X:132826430 C>G), RS1000154441 (X:132698352 C>G), RS1000162888 (X:132733560 A>T), RS1000166672 (X:132916453 T>C), RS1000171051 (X:132696379 C>T)

Disease associations

OMIM: gene MIM:300545 | disease phenotypes: MIM:301025

GenCC curated gene-disease

Disease	Classification	Inheritance
Paganini-Miozzo syndrome	Limited	X-linked

Mondo (1): Paganini-Miozzo syndrome (MONDO:0026724)

Orphanet (0):

HPO phenotypes

26 total (26 of 26 shown, HPO-id order):

HPO	Term
HP:0000020	Urinary incontinence
HP:0000233	Thin vermilion border
HP:0000272	Malar flattening
HP:0000303	Mandibular prognathia
HP:0000325	Triangular face
HP:0000341	Narrow forehead
HP:0000358	Posteriorly rotated ears
HP:0000369	Low-set ears
HP:0000490	Deeply set eye
HP:0000494	Downslanted palpebral fissures
HP:0000750	Delayed speech and language development
HP:0001263	Global developmental delay
HP:0001419	X-linked recessive inheritance
HP:0002003	Large forehead
HP:0002151	Increased circulating lactate concentration
HP:0002373	Febrile seizure (within the age range of 3 months to 6 years)
HP:0002465	Poor speech
HP:0002714	Downturned corners of mouth
HP:0003348	Hyperalaninemia
HP:0006956	Lateral ventricle dilatation
HP:0008551	Microtia
HP:0011003	High myopia
HP:0011463	Childhood onset
HP:0011968	Feeding difficulties
HP:0031936	Delayed ability to walk
HP:0032653	Elevated lactate:pyruvate ratio

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002127_28	Periodontitis (Mean PAL)	9.000000e-06
GCST006442_462	Educational attainment (years of education)	9.000000e-13
GCST90000050_86	Age at first birth	4.000000e-13

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004784	self reported educational attainment
EFO:0009101	age at first birth measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases methylation, affects expression, increases expression	6
methylmercuric chloride	decreases expression, increases expression, affects cotreatment	3
trichostatin A	increases expression	2
Benzo(a)pyrene	affects expression, affects methylation	2
Estradiol	decreases expression, affects cotreatment	2
Tobacco Smoke Pollution	decreases methylation, increases expression	2
Tretinoin	decreases expression	2
aristolochic acid I	decreases expression	1
propionaldehyde	increases expression	1
arsenite	increases methylation	1
sodium arsenite	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
beta-methylcholine	affects expression	1
glycidamide	decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
incobotulinumtoxinA	decreases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	increases expression	1
Vorinostat	increases expression	1
Calcitriol	increases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Fluorouracil	decreases expression	1
Lead	affects expression	1
Methotrexate	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.